Literature DB >> 21247686

Hippo signaling in oval cells and hepatocarcinogenesis.

Tongsen Zheng1, Jiabei Wang, Hongchi Jiang, LianXin Liu.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies and the third leading cause of cancer mortality world wide. Despite continuing development of new therapies, the prognosis for patients with HCC remains extremely poor. In part, this may relate to molecular abnormalities that stimulate HCC tumorigenesis and also contribute to reduced sensitivity to standard treatment. Increasing evidence has revealed the importance of liver cancer stem cells in hepatocarcinogenesis. Although widely investigated, the signaling pathways important for liver cancer stem cells in liver tumor initiation and progression are poorly understood. The Hippo signaling pathway was identified in Drosophila as an essential regulator of cell proliferation and apoptosis. Recently, Hippo pathway has been implicated in multiple events during development and it has also been proposed to play a vital role in several tumor types, especially in hepatocellular carcinoma. Strong evidences also proved the significant role of the Hippo signaling pathway in oval cell activation. As suggested, hippo signaling has a dual regulation of Hippo in liver tumor suppression as well as transition of oval cells to fully differentiated hepatocytes. Delineation of the malfunction of Hippo signaling pathway in HCC may lead to better understanding of hepatocarcinogenesis, rational medical therapy for HCC and possible therapy for other tumors. Here, we provide a historical review of this potent growth-regulatory pathway in HCC and highlight outstanding questions that will likely be the focus of future investigation. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21247686     DOI: 10.1016/j.canlet.2010.12.008

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  Expression of receptor interacting protein 1 and receptor interacting protein 3 oval cells in a rat model of hepatocarcinogenesis.

Authors:  Marta Wójcik; Ryszard Bobowiec; Urszula Lisiecka; Anna Śmiech
Journal:  Exp Ther Med       Date:  2018-03-22       Impact factor: 2.447

2.  Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling.

Authors:  Guobin He; Debanjan Dhar; Hayato Nakagawa; Joan Font-Burgada; Hisanobu Ogata; Yuhong Jiang; Shabnam Shalapour; Ekihiro Seki; Shawn E Yost; Kristen Jepsen; Kelly A Frazer; Olivier Harismendy; Maria Hatziapostolou; Dimitrios Iliopoulos; Atsushi Suetsugu; Robert M Hoffman; Ryosuke Tateishi; Kazuhiko Koike; Michael Karin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma.

Authors:  Showkat A Malik; Mosin S Khan; Majeed Dar; Mahboob Ul Hussain; Mohammad A Shah; Sheikh M Shafi; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2017-04-22       Impact factor: 3.201

4.  Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model.

Authors:  Nancy A Jenkins; Neal G Copeland; Emilie A Bard-Chapeau; Anh-Tuan Nguyen; Alistair G Rust; Ahmed Sayadi; Philip Lee; Belinda Q Chua; Lee-Sun New; Johann de Jong; Jerrold M Ward; Christopher Ky Chin; Valerie Chew; Han Chong Toh; Jean-Pierre Abastado; Touati Benoukraf; Richie Soong; Frederic A Bard; Adam J Dupuy; Randy L Johnson; George K Radda; Eric Cy Chan; Lodewyk Fa Wessels; David J Adams
Journal:  Nat Genet       Date:  2013-12-08       Impact factor: 38.330

5.  RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer.

Authors:  S E Lee; J U Lee; M H Lee; M J Ryu; S J Kim; Y K Kim; M J Choi; K S Kim; J M Kim; J W Kim; Y W Koh; D-S Lim; Y S Jo; M Shong
Journal:  Oncogenesis       Date:  2013-07-15       Impact factor: 7.485

6.  Alcohol interacts with genetic alteration of the Hippo tumor suppressor pathway to modulate tissue growth in Drosophila.

Authors:  Anoj Ilanges; Maryam Jahanshahi; Denis M Balobin; Cathie M Pfleger
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

7.  Two-signal requirement for growth-promoting function of Yap in hepatocytes.

Authors:  Tian Su; Tanya Bondar; Xu Zhou; Cuiling Zhang; Hang He; Ruslan Medzhitov
Journal:  Elife       Date:  2015-02-10       Impact factor: 8.140

8.  Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease.

Authors:  Maria M Simile; Gavinella Latte; Maria I Demartis; Stefania Brozzetti; Diego F Calvisi; Alberto Porcu; Claudio F Feo; Maria A Seddaiu; Lucia Daino; Carmen Berasain; Maria L Tomasi; Matias A Avila; Francesco Feo; Rosa M Pascale
Journal:  Oncotarget       Date:  2016-08-02

9.  The hippo-yes association protein pathway in liver cancer.

Authors:  Lu Jie; Wang Fan; Dai Weiqi; Zhou Yingqun; Xu Ling; Shen Miao; Cheng Ping; Guo Chuanyong
Journal:  Gastroenterol Res Pract       Date:  2013-08-06       Impact factor: 2.260

10.  Proliferation versus regeneration: the good, the bad and the ugly.

Authors:  George I Lambrou; Eumorphia Remboutsika
Journal:  Front Physiol       Date:  2014-01-28       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.